8-K: McKesson Reports Strong Q2, Raises FY26 EPS Guidance

McKesson Corporation announced record second quarter revenues and a significant increase in adjusted earnings per diluted share, leading to an upward revision of its full-year fiscal 2026 adjusted EPS guidance.

Summary

• Consolidated revenues reached a record high of $103.2 billion for the second quarter ended September 30, 2025, marking a 10% increase compared to the prior year.
• Earnings per diluted share (GAAP) increased significantly to $8.92, up $7.05 from $1.87 in the prior year, primarily due to the absence of prior year charges related to the sale of Canadian retail businesses and business rationalization initiatives.
• Adjusted Earnings per Diluted Share (Non-GAAP) grew 39% to $9.86, driven by strong operational growth, contributions from acquisitions, net gains in the Oncology & Multispecialty segment, and a lower tax rate.
• Generated $2.4 billion of cash flow from operations and $2.2 billion of Free Cash Flow during the second quarter.
• Raised Fiscal 2026 Adjusted Earnings per Diluted Share guidance range to $38.35 to $38.85, an increase of $0.30 from the previous range, indicating 16% to 18% growth compared to the prior year.
• Entered into a definitive agreement on August 4, 2025, to sell its retail and distribution businesses in Norway, subject to customary closing conditions.
• Announced changes to reportable segments and organizational structure on September 18, 2025, effective in the second quarter of fiscal 2026, to enhance strategic alignment and transparency.
• Hosted an Investor Day on September 23, 2025, where management highlighted progress against growth strategies and updated long-term financial targets.
• Expanded its oncology and multispecialty platform with PRISM Vision Group adding Spokane Eye Clinic on October 31, 2025.

Sentiment

Score: 9

Explanation: The company reported record revenues, significant growth in adjusted earnings per diluted share, and strong cash flow. Management raised full-year adjusted EPS guidance, indicating confidence in continued performance and strategic execution in high-growth areas like oncology and biopharma services.

Positives

• Record quarterly consolidated revenues of $103.2 billion, representing a 10% increase year-over-year.
• GAAP Earnings per diluted share surged to $8.92, an increase of $7.05, or 377%, compared to the prior year.
• Adjusted Earnings per Diluted Share increased 39% to $9.86, reflecting strong operational growth across the business.
• Generated robust cash flow from operations of $2.4 billion and Free Cash Flow of $2.2 billion in the second quarter.
• Raised Fiscal 2026 Adjusted Earnings per Diluted Share guidance by $0.30, now projecting 16% to 18% growth compared to the prior year.
• North American Pharmaceutical segment revenues increased 8%, driven by increased prescription volumes and specialty products.
• Oncology & Multispecialty segment revenues grew 32%, with Adjusted Segment Operating Profit increasing 71% due to provider and specialty distribution growth, acquisitions, and net gains.
• Prescription Technology Solutions segment revenues rose 9%, and Adjusted Segment Operating Profit increased 20% due to higher demand for access solutions.
• Returned $1.6 billion of cash to shareholders in the first six months of the fiscal year, including $1.4 billion in common stock repurchases and $179 million in dividend payments.
• Successful expansion of the oncology and multispecialty platform with the addition of Spokane Eye Clinic by PRISM Vision Group.

Negatives

• Medical-Surgical Solutions segment revenues were flat compared to the prior year, despite higher volumes of specialty pharmaceuticals.
• The Medical-Surgical Solutions segment experienced lower contributions from illness season products and testing, partially offsetting operational efficiencies.

Risks

• Experiencing costly and disruptive legal disputes and settlements, including regarding the role in distributing controlled substances such as opioids.
• Experiencing losses not covered by insurance or indemnification.
• Subject to frequently changing, extensive, complex, and challenging healthcare and other laws and policies.
• Recording significant charges from impairment to goodwill, intangibles, and other long-lived assets.
• Experiencing cybersecurity incidents that might significantly compromise technology systems or result in material data breaches.
• Experiencing significant problems with information systems or networks.
• Unsuccessful in achieving strategic growth objectives.
• Unsuccessful in efforts to implement initiatives to reduce or optimize costs.
• Inability to successfully complete or integrate acquisitions or other strategic transactions, especially in the timeframes noted.
• May not receive anticipated benefits from acquisitions or other strategic transactions.
• Adversely impacted by delays or other difficulties with divestitures.
• Impacted by customer purchase reductions, contract non-renewals, payment defaults, and bankruptcies.
• Contracts with government entities involve funding, payment, and compliance risks.
• Harm by changes in relationships or contracts with suppliers.
• Use of third-party data is subject to risks and limitations that could impede the growth of data services business.
• Inability to successfully recruit and retain qualified employees.
• Adversely impacted by healthcare reform such as changes in pricing and reimbursement models.
• Adversely impacted by competition and industry consolidation.
• Adversely impacted by changes or disruptions in product supply and difficulties in sourcing or selling products due to a variety of causes.
• Adversely impacted as a result of distribution of generic pharmaceuticals.
• Adversely impacted by changes in the economic environments in which operations occur.
• Changes affecting capital and credit markets might impede access to credit, increase borrowing costs, and disrupt banking services, and might impair the financial soundness of customers and suppliers.
• Adversely impacted by changes in tax legislation or challenges to tax positions.
• Adversely impacted by conditions and events outside of control, such as widespread public health issues, natural disasters, and geopolitical factors.
• Adversely affected by global climate change or by regulatory or market responses to such change.
• Evolving expectations and regulatory requirements related to governance and sustainability matters may have an adverse effect on business, financial condition, and results of operations and damage reputation.

Future Outlook

McKesson raised its fiscal 2026 Adjusted Earnings per Diluted Share guidance range to $38.35 to $38.85, an increase of $0.30 from the previous range. This updated guidance projects 16% to 18% growth compared to the prior year, reflecting sustained momentum across the portfolio and confidence in the outlook for the remainder of the year. The company does not provide forward-looking guidance on a GAAP basis.

Management Comments

• "McKesson's second quarter results underscore the strength of our differentiated assets, capabilities, and continued momentum as a diversified healthcare services leader."
• "We delivered record revenue in the quarter of $103 billion, increasing 10% and Adjusted Earnings per Diluted Share accelerating 39% compared to the prior year."
• "These results reflect disciplined execution of our enterprise strategy advancing growth in oncology and multispecialty and biopharma services."
• "We remain confident in our ability to create value for our customers, partners, employees, and shareholders."
• "These achievements reflect the dedication of McKesson employees and their unwavering commitment to delivering measurable value to all stakeholders."
• "Our strategic focus in our growth pillars of oncology and multispecialty and biopharma services, combined with disciplined execution, continues to drive sustainable long-term growth."
• "Following our strong first half performance, sustained momentum across our portfolio, and confidence in the outlook for the remainder of the year, we are raising our fiscal 2026 Adjusted Earnings per Diluted Share guidance by $0.30 to a range of $38.35 to $38.85. This builds on the $0.80 increase announced at Investor Day in September 2025."

Industry Context

McKesson's strong second-quarter performance, particularly its growth in oncology, multispecialty, and biopharma services, aligns with broader healthcare industry trends focusing on specialized care and pharmaceutical distribution efficiency. The company's strategic portfolio adjustments, including the divestiture of its Norwegian businesses and expansion of its oncology platform, reflect a strategic pivot towards higher-growth, higher-margin healthcare services, a common strategy among diversified healthcare leaders seeking to optimize value in a dynamic market.

Corporate Governance

Legal Proceedings

• The company faces risks related to costly and disruptive legal disputes and settlements, including those concerning its role in distributing controlled substances such as opioids.
• Claims and litigation charges for the six months ended September 30, 2024, included pre-tax charges of $114 million related to estimated liability for opioid-related claims of a nationwide group of certain third-party payors.

Stakeholder Impact

• Shareholders are positively impacted by strong financial results, increased EPS guidance, and significant cash returns through share repurchases and dividends.
• Customers and partners benefit from continued value creation through differentiated assets and capabilities, particularly in expanding oncology and multispecialty and biopharma services.
• Employees' dedication was acknowledged by the CEO, and the strategic focus on growth pillars may offer new opportunities.
• Creditors are likely to view the company favorably due to strong cash flow generation and overall robust financial performance.

Next Steps

• McKesson management will participate in the UBS Global Healthcare Conference on November 10, 2025.
• McKesson management will participate in the Evercore HealthCONx Conference on December 4, 2025.
• McKesson management will participate in the J.P. Morgan Healthcare Conference from January 12-15, 2026.
• The transaction to sell retail and distribution businesses in Norway is subject to customary closing conditions, including receipt of required approvals.

Key Dates

Recommendation

McKesson delivered exceptional second-quarter results, exceeding expectations with record revenues and a substantial 39% increase in Adjusted Earnings per Diluted Share. The company's decision to raise its full-year fiscal 2026 Adjusted EPS guidance by $0.30, building on a previous $0.80 increase, signals strong confidence in its strategic execution and sustained momentum, particularly in high-growth areas like oncology and biopharma services. Robust cash flow generation and significant capital returns to shareholders further enhance its investment appeal. These factors collectively point to a very positive outlook for the stock.

Keywords

Healthcare services, Pharmaceutical distribution, Oncology, Biopharma services, Specialty distribution, Earnings report, Financial guidance, Cash flow, Acquisitions, Divestitures, Corporate strategy, McKesson